The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) The planned clinical study will be executed ...

Credit: Thinkstock Investigators attending ASN’s Kidney Week 2024 reported progress on a number of IgA nephropathy drug ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...

Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...

Nattawat Klomjit, MD, shares insights on managing IgA nephropathy and C3 glomerulopathy, including innovative drugs that target kidney inflammation and proteinuria.

U.S. policies that fix the IRA, strengthen patents, and incentivize antimicrobial research could help hasten new medicines ...

PDS Biotechnology shares declined after it issued an update about a cancer study with a combination of Versamune HPV and pembrolizumab and reported quarterly results. The stock was down 18%, to $2.25, ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...